Premium
Nab‐Paclitaxel: a bright new SPARC in taxane therapy of cancer
Author(s) -
Ackland Stephen P,
Bull James M,
Boyle Frances M
Publication year - 2009
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2009.01233.x
Subject(s) - paclitaxel , medicine , taxane , adverse effect , drug , pharmacology , cancer , adjuvant , ixabepilone , breast cancer , oncology , metastatic breast cancer
A paper in this issue exemplifies two issues that deserve consideration in the clinical research and practice of oncology: 1) adverse events that occur in response to anticancer therapy may be due to excipients rather than the active agent, and the use of a different formulation may be effective; 2) differences in pharmacology and metabolism need to be considered whenever a drug is applied in different ethnic groups